Andrew M. Lowy

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• HDAC inhibition sensitizes pancreatic tumors to DNA damage by global redistribution of the transcriptional machinery

  Proceedings of the National Academy of Sciences · 2026-06-25

• Bridging the Gap: Examining the Association of Travel Burden With Treatment Administration and Survival in Stage II/III Gastric Cancer

  JCO Oncology Practice · 2026-06-23

• Supplementary Data from Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

  2026-06-19

• Supplementary Data from Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

  2026-06-18

• Fig. S7 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Fig. S1 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Supplementary Data from Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Table S2 from Dual Inhibition of KRAS<sup>G12D</sup> and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Table S3 from Dual Inhibition of KRAS<sup>G12D</sup> and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Fig. S5 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Table S1 from Dual Inhibition of KRAS<sup>G12D</sup> and Pan-ERBB Is Synergistic in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Fig. S3 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Fig. S2 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Fig. S6 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Supplementary Data from Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Supplementary Data from Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma

  2026-06-17

• Fig. S4 from Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

  2026-06-17

• Adjuvant Chemotherapy +/- Chemoradiotherapy for Adenocarcinoma of The Pancreatic Head: Results of The Radiotherapy Randomization of NRG Oncology/RTOG 0848

  Journal of Clinical Oncology · 2026-06-09

• Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.

  Journal of Clinical Oncology · 2026-05-27

• HDAC Inhibition Sensitizes Pancreatic Tumors to DNA Damage by Global Redistribution of the Transcriptional Machinery

  bioRxiv (Cold Spring Harbor Laboratory) · 2026-05-19